In San Diego, synthetic biology company Debut has closed a substantial $40 million Series B funding, led by L’Oréal’s venture capital fund, BOLD. The investment will bolster Debut’s efforts to redefine the fragrance industry by developing bio-identical and novel fragrance molecules using cutting-edge biomanufacturing techniques.
Debut uses a vertically integrated approach, which harnesses advanced biomanufacturing to unlock a new generation of cosmetic bioactive ingredients. Debut’s technology aims to enable fragrance brands to transition to biobased formulas while preserving the authentic scent profiles of their products. The company says its technology can faithfully replicate the intricate characteristics of natural ingredients, including rare and complex compounds that are often challenging to source in nature. Additionally, Debut will pioneer the development of entirely new fragrance molecules.
More on the story.
Category: Chemicals & Materials
